GBT Financial Facts

Weighted average number of common shares outstanding - basic: 76.44M
Research and development expenses: 298.26K
See Full Income Statement

Advance to suppliers, net: 7.56M
Total Current Liabilities: 8.14M
See Full Balance Sheet

Global Blood Therapeutics (GBT) Earnings

  |   Expand Research on GBT
Next EPS Date 2/23/23 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate -1.8% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -6.7% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/3/22 Q322 N/A-$1.12 N/A N/A$75.79M N/A N/A N/A
8/8/22 Q222 -$1.12-$1.18 +$0.06$47.56M$64.39M N/A Details
8/8/22 Q222 -$1.12-$1.18 +$0.06$47.56M$64.39M N/A Details
5/4/22 Q122 -$1.26-$1.30 +$0.04$55.16M$56.14M N/A Details
2/23/22 Q421 -$1.36-$1.13 -$0.23$56.1M$55.44M N/A Details
11/4/21 Q321 N/A-$1.11 N/A N/A$53.7M N/A N/A N/A
11/5/20 Q320 -$0.97-$0.73 -$0.24$36.89M$43.98M N/A Details
8/3/21 Q221 -$1.12-$1.19 +$0.07$47.6M$43.84M N/A Details